Literature DB >> 22958154

Treatment of Helicobacter pylori infection 2012.

Bojan Tepes1, Anthony O'Connor, Javier P Gisbert, Colm O'Morain.   

Abstract

Helicobacter pylori resistance rates to antibiotics vary in different countries and even in different regions of the same country. Choice of treatment is strongly dependent on antibiotic resistance rates. In some countries, triple therapy with a proton-pump inhibitor, amoxicillin, and clarithromycin is still the best option, but eradication results fall short of what would be desired (90-95%) in countries with clarithromycin resistance >20%, bismuth-containing quadruple therapy, or nonbismuth sequential or concomitant therapies may then be the preferred option. Newer antibiotic regimens are awaited. Vaccination would be the best option, especially for developing countries, but little progress has been made in designing a vaccine.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22958154     DOI: 10.1111/j.1523-5378.2012.00981.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  12 in total

1.  Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity.

Authors:  John G Nedrud; Nayer Bagheri; Karin Schön; Wei Xin; Hilda Bergroth; Dubravka Grdic Eliasson; Nils Y Lycke
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

2.  Impact of Helicobacter pylori Infection and Outcome of Anti-Helicobacter pylori Therapy in Patients with Reflux Laryngopharyngitis.

Authors:  Huili Shen; Yijie Chen; Xiaohui Li; Jing Yan; Junjie Zhao; Demin Kong; Yanxia Shi; Zhihui Li; Jihong Wang; Na Shao; Zhenghui Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-05       Impact factor: 2.650

Review 3.  Helicobacter pylori research: historical insights and future directions.

Authors:  Kwong Ming Fock; David Y Graham; Peter Malfertheiner
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-06-11       Impact factor: 46.802

4.  Recombinant Bacillus subtilis Spores Elicit Th1/Th17-Polarized Immune Response in a Murine Model of Helicobacter pylori Vaccination.

Authors:  Małgorzata Stasiłojć; Krzysztof Hinc; Grażyna Peszyńska-Sularz; Michał Obuchowski; Adam Iwanicki
Journal:  Mol Biotechnol       Date:  2015-08       Impact factor: 2.695

5.  Is There Any Advantage of Treating Partners in Helicobacter pylori Eradication?

Authors:  Halil Rakici; Remzi Adnan Akdogan; Teslime Ayaz; Recep Bedir
Journal:  Gastroenterol Res Pract       Date:  2015-03-15       Impact factor: 2.260

Review 6.  Novel Idea: Virulence-Based Therapy Against Helicobacter pylori Infection (Smart Therapy).

Authors:  Amin Talebi Bezmin Abadi
Journal:  Front Med (Lausanne)       Date:  2014-06-23

7.  The effects of probiotics on treatment of Helicobacter pylori eradication in children.

Authors:  Mustafa Akcam; Tugba Koca; Hakan Salman; Nermin Karahan
Journal:  Saudi Med J       Date:  2015-03       Impact factor: 1.484

8.  Important Role of a Putative Lytic Transglycosylase Cj0843c in β-Lactam Resistance in Campylobacter jejuni.

Authors:  Ximin Zeng; Barbara Gillespie; Jun Lin
Journal:  Front Microbiol       Date:  2015-11-17       Impact factor: 5.640

Review 9.  Therapy of Helicobacter pylori: present medley and future prospective.

Authors:  Amin Talebi Bezmin Abadi
Journal:  Biomed Res Int       Date:  2014-04-01       Impact factor: 3.411

10.  Saccharomyces Boulardii in Helicobacter Pylori Eradication in Children: A Randomized Trial From Iran.

Authors:  Kokab Namkin; Mahmood Zardast; Fatemeh Basirinejad
Journal:  Iran J Pediatr       Date:  2016-01-30       Impact factor: 0.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.